Spruce Biosciences, Inc. (SPRB) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
SPRB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SPRB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 100.0% | -1143.4% | -1079.9% |
| 2023 | 100.0% | -515.3% | -475.0% |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export SPRB earnings history in CSV or JSON format
Free sign-in required to download data
Spruce Biosciences, Inc. (SPRB) Earnings Overview
As of May 8, 2026, Spruce Biosciences, Inc. (SPRB) reported trailing twelve-month net income of -$39M, reflecting +47.5% year-over-year growth. The company earned $-50.83 per diluted share over the past four quarters.
Looking at the long-term picture, SPRB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2018.
Spruce Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CORT ($48M net income, 13.1% margin), XNCR (-$172M net income, -73.2% margin), NTLA (-$413M net income, -609.9% margin), SPRB has comparable earnings metrics. Compare SPRB vs CORT →
SPRB Earnings vs Peers
Earnings metrics vs comparable public companies
SPRB Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$39M | +26.5% | -$37M | $-50.83 | - | - |
| 2024 | -$53M | -10.7% | -$56M | $-96.75 | -1079.9% | -1143.4% |
| 2023 | -$48M | -3.8% | -$52M | $-93.00 | -475.0% | -515.3% |
| 2022 | -$46M | -9.2% | -$47M | $-72.00 | - | - |
| 2021 | -$42M | -43.2% | -$42M | $-68.25 | - | - |
| 2020 | -$30M | -123.2% | -$29M | $-48.75 | - | - |
| 2019 | -$13M | -34.3% | -$13M | $-22.50 | - | - |
| 2018 | -$10M | - | -$10M | $-483.75 | - | - |
See SPRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SPRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SPRB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSPRB — Frequently Asked Questions
Quick answers to the most common questions about buying SPRB stock.
Is SPRB growing earnings?
SPRB EPS is $-50.83, with earnings growth accelerating to +47.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-39M.
What are SPRB's profit margins?
Spruce Biosciences, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SPRB's earnings?
SPRB earnings data spans 2018-2025. The accelerating earnings trend is +47.5% YoY. Historical data enables comparison across business cycles.